Table 1.
Characteristics of subjects with T2D selected for nested case-controls study
| Baseline characteristic | Study groups: | ||
|---|---|---|---|
| Non-progressors | ESRD progressors | ||
| Controls (n=40) | Cases (n=40) | p value* | |
| Male (%) | 62 | 55 | n.s |
| Age (yr) | 56±11 | 59±7 | n.s |
| Duration of diabetes (yr) | 13±7 | 17±7 | n.s |
| Body mass index (kg/m2) | 29.7±5.9 | 31.5±7.1 | n.s |
| HbA1c (%) | 8.8±1.4 | 9.3±2.0 | n.s |
| Serum cholesterol (mg/dl) | 241±62 | 234±54 | n.s |
| Systolic blood pressure (mmHg) | 135±25 | 142±32 | n.s |
| Antihypertensive/renoprotective Treatment [%] | 74% | 62% | n.s |
| ACR (μg/g creatinine) | 308 (70,471) | 957 (382, 2265) <0.0001 | |
| eGFR (ml/min/1.73m2) | 87±23 | 75±19 | <0.01 |
| CKD stage 1 | 38% | 20% | |
| stage 2 | 55% | 58% | n.s. |
| stage 3 | 7% | 22% | |
| Parathormone (pg/ml) |
15 (9, 20) | 16 (10,31) | n.s. |
| Length of the follow up (years) | 10 (8, 12) | 7 (4, 9)† | 0.008 |
Proportion, mean ± standard deviation or median (25th, 75th percentile) are presented.
Abbreviations: T2D – type 2 diabetes, ESRD end-stage renal disease, ACR – albumin to creatinine ratio, eGFR – estimated glomerular filtration rate, HbA1c – hemoglobin A1c.
*
Bonferroni corrected
†
until ESRD development.